Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-NDActa pharmaceutica Sinica. B

A probiotic–drug cascade system for inflammatory bowel disease via tryptophan metabolism and gut microbiome remodeling

  • Junfei Yang1
  • Zuer Feng1
  • Shuxin Sun1
  • Tianqi Pei1
  • Yunfei Li1
  • Beiyang Xue1
  • Chuangxi Zhou1
  • Qingling Song1
  • Yun Zhang1
  • Lei Wang1
  1. 1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
Read full textPDFDOICite

Abstract

The development of oral therapeutics capable of improving tryptophan metabolism and restoring gut microbiome homeostasis is vital for effective inflammatory bowel disease (IBD) management. Despite the significant advancements in bacteriotherapy for IBD, current strategies often suffer from limited functionalities and compromised efficacy due to the multifaceted nature of gastrointestinal tract physiology and pathology. Here, we propose an acid-resistant and microenvironment-responsive probiotic–drug codelivery system (BS@MPN-BBR@S100) based on the metal–phenolic network (MPN). Following oral administration, the dual MPN-S100 coating significantly enhances probiotic survival in the face of gastrointestinal challenges, including gastric acid and proteases, promoting targeted adhesion to colonic lesions. Impressively, the loaded berberine (BBR) is released in a targeted, calprotectin (CP)-responsive manner at disease sites, thereby effectively restoring intestinal barrier function by remodeling tryptophan metabolism. In a murine model of colitis, BS@MPN-BBR@S100 effectively alleviated disease symptoms by regulating tryptophan metabolism, reshaping microbiome homeostasis, and alleviating oxidative stress. Overall, this study addresses key bottlenecks in oral probiotics and drug delivery, offering a promising strategy for developing effective therapeutics against IBD.

Related

  1. Gut microbiome-derived metabolic remodeling and the butyrate-IL-18 inflammatory axis after transcatheter aortic valve implantation
    C. Chong-Nguyen, C. Ferro, B. Yilmaz +7
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  2. Tryptophan Metabolism in Pediatric Atopic Dermatitis: Shared Mechanisms, Age-Specific Biomarkers, and Emerging Therapies
    Marta Dyszkiewicz, Beata Cudowska, Wioleta Justyna Omeljaniuk +2
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Tumour rewires host tryptophan metabolism to promote organism-wide immune suppression
    L. Garcia-Lopez, E. Saez-Carrion, M. L. Uribe +4
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. Behavioral dysfunction but not wasting in cancer cachexia is driven by altered tryptophan metabolism
    D. Fard, E. Pirani, M. Gomez-Jenkins +16
    bioRxivPreprintCC BYFull textOncologybioRxiv
  5. Tryptophan metabolism circadian regulation: clinical and pharmacological implications
    Consuelo Fabi, Sarah Balucchi, Marina Maria Bellet
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPhysiologyCrossrefPMC

Cite

BibTeXRIS
BibTeX
@article{yang2026probioticdrug,
  title = {{A probiotic–drug cascade system for inflammatory bowel disease via tryptophan metabolism and gut microbiome remodeling}},
  author = {Junfei Yang and Zuer Feng and Shuxin Sun and Tianqi Pei and Yunfei Li and Beiyang Xue and Chuangxi Zhou and Qingling Song and Yun Zhang and Lei Wang},
  journal = {Acta pharmaceutica Sinica. B},
  year = {2026},
  month = jul,
  doi = {10.1016/j.apsb.2026.07.013},
  url = {https://europepmc.org/article/PMC/PMC13730227},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - A probiotic–drug cascade system for inflammatory bowel disease via tryptophan metabolism and gut microbiome remodeling
AU  - Junfei Yang
AU  - Zuer Feng
AU  - Shuxin Sun
AU  - Tianqi Pei
AU  - Yunfei Li
AU  - Beiyang Xue
AU  - Chuangxi Zhou
AU  - Qingling Song
AU  - Yun Zhang
AU  - Lei Wang
PY  - 2026
DA  - 2026/07/11
JO  - Acta pharmaceutica Sinica. B
DO  - 10.1016/j.apsb.2026.07.013
UR  - https://europepmc.org/article/PMC/PMC13730227
AB  - The development of oral therapeutics capable of improving tryptophan metabolism and restoring gut microbiome homeostasis is vital for effective inflammatory bowel disease (IBD) management. Despite the significant advancements in bacteriotherapy for IBD, current strategies often suffer from limited functionalities and compromised efficacy due to the multifaceted nature of gastrointestinal tract physiology and pathology. Here, we propose an acid-resistant and microenvironment-responsive probiotic–drug codelivery system (BS@MPN-BBR@S100) based on the metal–phenolic network (MPN). Following oral administration, the dual MPN-S100 coating significantly enhances probiotic survival in the face of gastrointestinal challenges, including gastric acid and proteases, promoting targeted adhesion to colonic lesions. Impressively, the loaded berberine (BBR) is released in a targeted, calprotectin (CP)-responsive manner at disease sites, thereby effectively restoring intestinal barrier function by remodeling tryptophan metabolism. In a murine model of colitis, BS@MPN-BBR@S100 effectively alleviated disease symptoms by regulating tryptophan metabolism, reshaping microbiome homeostasis, and alleviating oxidative stress. Overall, this study addresses key bottlenecks in oral probiotics and drug delivery, offering a promising strategy for developing effective therapeutics against IBD.
SN  - 2211-3835
SN  - 2211-3843
ER  -